PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$11.85
0.17 (1.46%)
â˛
5d:
+1.11%
30d:
-10.02%
90d:
-7.49%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PHAR is fairly priced but lacks strong directional signals. At -43.2% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PHAR is fairly priced but lacks strong directional signals. At -43.2% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.27
Based on -14.6% avg growth
INTRINSIC VALUE TODAY
$2.03
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $11.85, which is considered fair relative to its 30-day fair value range of $10.91 to $13.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 38.0) compared to its historical average (207.3). Remarkably, the market is currently pricing in an annual earnings decline of 43.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAR is in a strong downtrend. Immediate support is located at $10.54, while resistance sits at $13.32.
Market Sentiment: PHAR scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.35 (+194.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAR is in a strong downtrend. Immediate support is located at $10.54, while resistance sits at $13.32.
Market Sentiment: PHAR scores 22/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.35 (+194.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.91 -
$13.01
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (22/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 194.1% below Wall St target ($34.35)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.91 -
$13.01
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$10.54
Resistance Level
$13.32
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
38.05
Wall Street Target
$34.35
(+194.1%)
Revenue Growth (YoY)
-3.2%
Earnings Growth (YoY)
-62.9%
Profit Margin
2.5%
Valuation Discount vs History
-43.2% cheaper
PE vs Historical
38.1 vs 207.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-43.2%
(market-implied from PE analysis)
1-Year Target
$10.51
(-10%)
2-Year Target
$9.46
(-19%)
3-Year Target
$8.51
(-27%)
3-Yr Target (if PE normalizes)
(PE: 38â207)
$46.39
(+297%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 38.0, Growth: -33.3%)
$8.51
(+-27%)
Base:
(SPY PE: 20.1, Growth: -33.3%)
$4.49
(-62%)
Bear:
(PE: 17.1, Growth: -33.3%)
$3.82
(-67%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (85x PE), but valuation improves significantly next year (38x PE) as earnings recover.
Trailing PE: 84.64 | Current EPS (TTM): $0.14
Bull Case
$26.07
(+120%)
Analyst growth 100.0%, PE expands to 93.1
Base Case
$23.70
(+100%)
Market implied 100.0%, PE stable at 84.6
Bear Case
$8.06
(-32%)
Severe decline -20.0%, PE contracts to 72.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 38.0 to 207.3
Stabilization Target:
$63.64
(+444.9%)
PE Expansion Potential:
+444.9%
Share & Embed Analysis
Last updated: August 23, 2026 8:27 PM ET
Data refreshes hourly during market hours. Next update: 9:27 PM
Data refreshes hourly during market hours. Next update: 9:27 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 40 SELL |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
